-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Upgrades Bicara Therapeutics to Equal-Weight, Maintains Price Target to $8

Benzinga·05/23/2025 18:11:04
Listen to the news
Wells Fargo analyst Eva Fortea Verdejo upgrades Bicara Therapeutics (NASDAQ:BCAX) from Underweight to Equal-Weight and maintains the price target from $8 to $8.